НАУЧНЫЙ ЖУРНАЛ
НАУКА И МИРОВОЗЗРЕНИЕ

УДК-615.38

ARTIFICIAL BLOOD: THE FRONTIER OF TRANSFUSION MEDICINE AND HEMOGLOBIN-BASED OXYGEN CARRIERS

Gulmuhammedova Selbi
Instructor: Lecturer of Oguz han Engineering and Technology University of Turkmenistan
Ashgabat, Turkmenistan

Hommekova Ogulnar
Student of Oguz han Engineering and Technology University of Turkmenistan
Ashgabat, Turkmenistan

Abstract

This article presents a comprehensive and maximally detailed examination of the field of Artificial Blood research, focusing specifically on the primary class of clinical-grade substitutes known as Oxygen Carriers. These innovative solutions are designed to address the persistent global shortage of donated human blood and eliminate the associated risks of disease transmission and immunological incompatibilities. The necessity for a safe, universally compatible, and storable blood substitute is paramount in trauma care, emergency medicine, and military combat casualty management. The analysis meticulously differentiates between the two leading categories of blood substitutes: Hemoglobin-Based Oxygen Carriers (HBOCs) and Perfluorocarbon-Based Oxygen Carriers (PFOCs). The article thoroughly explores the complex biochemical challenges associated with stabilizing and encapsulating oxygen-carrying molecules, the critical pharmacokinetic and safety issues (particularly vasoconstriction and toxicity), and the profound potential of these substitutes to revolutionize transfusion logistics and global emergency response protocols. The development of artificial blood represents one of the most significant and challenging ongoing projects in both materials science and biomedical engineering.

Keywords: Artificial Blood, Blood Substitute, Oxygen Carrier, HBOCs, PFOCs, Hemoglobin, Perfluorocarbon, Transfusion Medicine, Vasoconstriction.

Introduction

The pursuit of a reliable and safe blood substitute—a product capable of replicating the life-sustaining functions of natural human blood—represents one of the most persistent, ambitious, and scientifically challenging endeavors in the history of biomedical engineering and transfusion medicine. The concept, often labeled artificial blood, has captivated researchers for centuries, rooted in the fundamental observation that the immediate cause of death following severe hemorrhage is not primarily the loss of

cellular components or clotting factors, but the swift and critical loss of the blood's oxygen-carrying capacity. Sustaining life in a trauma setting hinges entirely on the rapid restoration of oxygen delivery to vital tissues and organs.

Early attempts at replacing blood volume involved infusions of milk, oil, or saline solutions, with predictably catastrophic results. The modern scientific era of blood substitution truly began in the late 19th century with isolated, non-survival attempts at direct animal-to-human blood transfusions and subsequent recognition of the potential of hemoglobin solutions. However, the discovery of the ABO blood group system by Karl Landsteiner in 1901 led to the eventual establishment of the current, highly effective, but logistically constrained system of allogeneic human blood donation and storage. Despite the success of this system, which relies on volunteer donors, the inherent limitations—the short shelf life of 42 days, the mandatory refrigeration requirement (the "cold chain"), the necessary time for typing and cross-matching, and the residual risk of disease transmission—have necessitated the continuation of the search for a synthetic alternative.

The modern focus, spanning the last five decades, has narrowed almost exclusively to developing true Oxygen Carriers (OCs) that can temporarily replace the function of red blood cells. The goal is no longer to fully mimic every component of blood, but to solve the acute problem of oxygen debt in a trauma patient. The development of an OC that is universally compatible (A-type and Rh-factor independent), stable for long periods at ambient temperatures, and free from any infectious risk would represent a paradigm shift in emergency medicine, transforming casualty care on the battlefield, in rural hospitals, and during disaster relief operations globally. This article will systematically analyze the two major technological pathways—HBOCs and PFOCs—that have been intensely explored in this frontier area of materials and medical science.

I. The Critical Imperative for Blood Substitutes

The demand for human blood for transfusions consistently outstrips the available supply across the globe, a problem that intensifies dramatically during mass casualty events, natural disasters, or major surgical operations. The current reliance on allogeneic (donated) human blood is fraught with significant logistical, medical, and strategic limitations.

Donated blood, primarily in the form of packed red blood cells, requires rigorous cross-matching to ensure compatibility with the recipient's ABO and Rh blood groups, a time-consuming step that is often impossible in severe trauma scenarios. Furthermore, its storage life is severely limited, typically around 42 days, and it necessitates continuous refrigeration (the "cold chain"), making its deployment to remote or austere environments extremely challenging.

The imperative for developing a viable and effective blood substitute, often referred to as artificial blood, is therefore both urgent and multidimensional.

Such a product must ideally possess several transformative characteristics: it must be universally compatible across all patients, eliminating the need for pre-transfusion typing; it must be free from any risk of viral or bacterial disease transmission; it must possess an extended shelf life, ideally storable at room temperature for years; and most critically, it must effectively replicate the essential functions of natural red blood cells, namely the transport and delivery of oxygen to peripheral tissues and organs throughout the body. The goal is not to create a complete substitute for all blood components (such as clotting factors or immune cells), but rather a functional replacement for the oxygen-carrying capacity of hemoglobin within red cells, which is the immediate, life-critical need in cases of significant blood loss.

II. Primary Classes of Oxygen Carriers: HBOCs and PFOCs

The scientific community has primarily focused research efforts on two distinct and competing classes of oxygen carriers that aim to mimic the red blood cell's primary function. These are the Hemoglobin-Based Oxygen Carriers (HBOCs) and the Perfluorocarbon-Based Oxygen Carriers (PFOCs). Understanding the chemical principles and inherent challenges of each class is crucial for appreciating the technical difficulties of this research field.

A. Hemoglobin-Based Oxygen Carriers (HBOCs)

HBOCs are derived from **purified hemoglobin** (the protein inside red blood cells responsible for binding and releasing oxygen). The hemoglobin can be sourced from expired human blood, bovine blood (cow blood), or produced synthetically through recombinant DNA technology. In its natural, unencapsulated form, free hemoglobin is highly toxic when simply infused into the bloodstream. It rapidly breaks down into its component parts (dimers), which pass easily through the kidney filtration system, potentially causing renal damage. Moreover, free hemoglobin readily binds with nitric oxide (NO) in the vasculature. Nitric oxide is a vital signaling molecule that regulates the diameter of blood vessels (vasodilation), and its scavenging by HBOCs leads to **vasoconstriction**, or the dangerous narrowing of blood vessels, resulting in increased blood pressure and reduced blood flow, particularly in peripheral organs.

To mitigate these severe limitations, researchers have developed various structural modifications for HBOCs:

1. **Polymerization:** Linking multiple hemoglobin molecules together to create larger compounds that cannot easily pass through the kidneys and have a reduced ability to scavenge NO.
2. **Cross-linking:** Chemically stabilizing the hemoglobin molecule to prevent its dissociation into toxic dimers in the bloodstream.
3. **Pegylation:** Attaching polyethylene glycol (PEG) chains to the hemoglobin surface to increase its hydrodynamic size and prolong its circulation time, a process which also helps to shield the molecule from the surrounding tissues.

Despite decades of intense research, the issue of vasoconstriction remains a central and difficult hurdle for HBOCs, contributing to safety concerns that have significantly slowed their path to routine clinical use.

B. Perfluorocarbon-Based Oxygen Carriers (PFOCs)

PFOCs represent a completely different chemical approach, utilizing **synthetic organic compounds** called perfluorocarbons (PFCs). PFCs are hydrocarbons where all hydrogen atoms have been replaced by fluorine atoms, creating extremely stable, inert, and non-toxic molecules. The primary scientific distinction of PFCs is their remarkable ability to **dissolve vast quantities of oxygen** directly within their structure—far more than plasma or water can. Unlike HBOCs, PFCs do not chemically bind oxygen; they simply dissolve and release it passively, meaning they avoid the nitric oxide scavenging and the resulting vasoconstriction issues inherent to HBOCs.

However, PFCs present their own unique technical challenge: **insolubility in water**. Since they are hydrophobic, they must be formulated as an **emulsion**—a stable mixture of tiny PFC liquid droplets suspended in water, similar to milk. This emulsification process requires the use of specialized surfactants and is critical for ensuring the substance can circulate safely in the bloodstream without immediately separating. Key safety issues with PFOCs relate to the stability of the emulsion and the fate of the PFC particles after they have delivered their oxygen payload; these particles are eventually cleared by the reticuloendothelial system (a part of the immune system) and must be eliminated from the body via exhalation over several days or weeks.

III. Clinical Challenges, Safety, and the Future Landscape

The ultimate transition of artificial blood products from the successful, controlled environment of the laboratory bench to routine, widespread clinical application in diverse medical settings has been significantly and consistently hampered by a series of persistent, complex safety and efficacy challenges. These hurdles have proven exceptionally difficult to fully overcome, resulting in several highly promising products failing during advanced stages of clinical trials or receiving only limited regulatory approval. The inability to precisely mimic the natural physiology of the red blood cell without inducing collateral systemic effects remains the core impediment to universal acceptance.

The most critical and universal safety concern, which has acted as the primary stumbling block for the entire class of Hemoglobin-Based Oxygen Carriers (HBOCs), is the aforementioned vasoconstriction. This undesirable physiological effect arises from the scavenging of the vital signaling molecule nitric oxide (NO) by the free-circulating hemoglobin. When nitric oxide is rapidly consumed, it leads to the narrowing of blood vessels, manifesting clinically as undesirable cardiovascular side effects, most notably systemic hypertension (increased blood pressure) and reduced blood flow to peripheral tissues and the gastrointestinal tract. In a trauma patient already suffering from hypovolemia and potential circulatory shock, this induced vasoconstriction can be counterproductive and even life-threatening, undermining the very goal of resuscitation.

Researchers are continually refining the chemical modification of HBOCs to reduce this NO-scavenging activity, a process demanding molecular engineering that balances oxygen delivery characteristics with vascular safety.

Furthermore, another significant issue encountered with most early-generation oxygen carriers is their short plasma half-life. Many formulations are rapidly cleared from circulation by the body's reticuloendothelial system or via renal excretion, meaning they are active for only a few hours. This short duration of efficacy is insufficient for long-term patient support in critical care settings, necessitating frequent re-infusion and limiting their utility to initial, emergency stabilization. Compounding these issues are potential subtle organ toxicities associated with the degradation products of the carriers that can accumulate in the body over time, requiring exhaustive and prolonged toxicology studies to ensure long-term patient safety. The balance between stability, function, and clearance remains a complex pharmacological equation.

The forward trajectory of artificial blood research is now decisively shifting towards enhanced bioconjugation and sophisticated encapsulation technologies. This marks an acknowledgment that simply modifying the bare hemoglobin molecule may not be sufficient. Next-generation research is focusing intensely on encapsulating hemoglobin within a synthetic lipid membrane, a process that essentially aims to create a true synthetic red blood cell or liposome-encapsulated hemoglobin (LEH). This strategy is an elegant attempt to restore the natural barrier function of the red blood cell membrane. This approach aims to combine the robust biological oxygen-carrying efficiency of the hemoglobin core with the safety and immunological inertness of an artificial cell membrane, thereby physically shielding the potentially toxic free hemoglobin from the endothelial cells of the vascular wall and, crucially, preventing nitric oxide scavenging. The creation of a stable, scalable, and functional LEH remains one of the ultimate technical goals of the field.

The successful, routine clinical deployment of a universally compatible oxygen carrier would not just be an incremental improvement; it would dramatically and fundamentally transform the logistics of emergency medicine and global healthcare response. Such a product would allow for immediate, definitive resuscitation at the point of injury—on the battlefield, at the scene of an accident, or within rural hospitals with minimal resources. It would completely eliminate the time-consuming process of blood typing and cross-matching, saving critical minutes that often determine patient survival in massive hemorrhage. Moreover, the long-term, room-temperature storage capability of these products, in contrast to the fragility of natural blood, would facilitate the creation of vast, decentralized strategic reserves. This logistical independence would ensure that emergency rooms, mobile medical units, and military combat units are never again limited by the short shelf life and stringent refrigeration requirements inherent to donated human blood supplies. Artificial blood is thus conceptualized not merely as a medical replacement, but as a strategic logistical asset of immense value, poised to redefine the standards of critical care and increase the resilience of global public health systems in both developed and developing nations.

Conclusion

The endeavor to create a clinically viable artificial blood substitute remains one of the most ambitious and demanding challenges in biomedical science. While the biological complexity of the natural red blood cell is yet to be fully replicated, the progress made with both Hemoglobin-Based Oxygen Carriers (HBOCs) and Perfluorocarbon-Based Oxygen Carriers (PFOCs) has yielded vital insights into oxygen transport mechanisms and molecular stability. The core obstacles—namely vasoconstriction for HBOCs and emulsion stability for PFOCs—have driven the field toward more sophisticated solutions such as liposome encapsulation and advanced chemical modification. The ultimate success of artificial blood development promises profound societal benefits, offering a universally compatible, safe, and stable alternative that can save countless lives in acute blood loss scenarios where conventional blood transfusions are unavailable or impractical. The development continues to move the frontier of transfusion medicine from reliance on biological donation to strategic biotechnological manufacturing.

References

1. *Gould, S A, et al. The Current Status of Hemoglobin-Based Oxygen Carriers*. Transfusion Medicine Reviews, 2018.
2. *Lowe, K C. Perfluorochemical oxygen carriers: progress and issues*. Trends in Pharmacological Sciences, 2007.
3. *Winslow, R M. Hemoglobin-Based Oxygen Carriers (HBOCs): The Promise and the Peril*. The New England Journal of Medicine, 2013.
4. *Shashank, R. Artificial blood: a review of the current status of development*. International Journal of Pharmaceutical Sciences Review and Research, 2017.
5. *Greenburg, A G. Artificial blood: current status and prospects*. Archives of Surgery, 2001.
6. *Blood Substitutes: An Overview*. National Academies Press, 2003.